{"filings":[{"id":156031,"accession_number":"0001641172-25-016833","cik":1569340,"company_name":"Cell Source, Inc.","ticker":"CLCS","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Cell Source replaces auditor Marcum with CBIZ CPAs after acquisition; going concern noted in prior reports","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum resigned as auditor on June 26, 2025; CBIZ CPAs engaged for year ended Dec 31, 2024.","Audit reports for 2022 and 2023 included a going-concern emphasis but no adverse opinion.","No disagreements or reportable events occurred with Marcum during the relevant periods.","Change triggered by CBIZ's November 1, 2024 acquisition of Marcum's attest business."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":56395065.874999985,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225430,"accession_number":"0001493152-24-014035","cik":1569340,"company_name":"Cell Source, Inc.","ticker":"CLCS","form_type":"8-K","filed_at":"2024-04-09T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cell Source completes $4.76M offering of 8% convertible notes with warrants","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Completed private offering of $4,760,170 aggregate principal of 8% convertible notes.","Notes are convertible into Series C Convertible Preferred Stock at $7.50 per share.","Issued warrants to purchase 4,321,926 common shares at $1.25 per share.","No additional subscriptions will be accepted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":56395065.874999985,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353592,"accession_number":"0001493152-22-019997","cik":1569340,"company_name":"Cell Source, Inc.","ticker":"CLCS","form_type":"8-K","filed_at":"2022-07-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Two directors resign from Cell Source board, no disagreements cited","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ben Friedman resigned as director on July 18, 2022.","David Zolty resigned as director on the same date.","Neither resignation was due to any disagreement with the company.","No replacements have been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":56395065.874999985,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371323,"accession_number":"0001493152-22-012387","cik":1569340,"company_name":"Cell Source, Inc.","ticker":"CLCS","form_type":"8-K","filed_at":"2022-05-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Itamar Shimrat resigns from board, remains CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["On May 6, 2022, Itamar Shimrat resigned as director of Cell Source, Inc.","Resignation not due to any disagreement; Mr. Shimrat continues as President and CEO.","Board restructured to an odd number of members to reduce deadlock risk."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":56395065.874999985,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390309,"accession_number":"0001493152-22-006672","cik":1569340,"company_name":"Cell Source, Inc.","ticker":"CLCS","form_type":"8-K","filed_at":"2022-03-11T23:59:59+00:00","items":["1.01","5.02"],"status":"ready","headline":"Cell Source issues $2.5M convertible note to new board member George Verstraete at 10% interest","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Appointed George Verstraete to the board; he agreed to loan $2.5M via a convertible promissory note.","Note bears 10% interest per annum, matures in 12 months from March 10, 2022.","Convertible into Series B Preferred Stock at $7.50/share; interest may be paid in cash or common stock at $0.75/share.","For each $500K advanced, Verstraete receives a warrant for 400K common shares at $1.25/share with a 5-year term."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":56395065.874999985,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}